Primary prostatic involvement in non-hodgkin lymphoma

Patel, Dhimant; Gómez, Germán A.; Henderson, Edward S.; Gamarra, Marie

doi:10.1016/0090-4295(88)90305-6

Cited by 30 publications

(18 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Almost all patients diagnosed with prostatic lymphoma, whether primary or secondary, present symptoms of lower urinary obstruction [2,3,5]. Some patients present pain or hematuria, and others present systemic symptoms.…”

Section: Discussionmentioning

confidence: 99%

Primary lymphoma of the prostate treated with rituximab-based chemotherapy: a case report and review of the literature

Taleb

Ismaili

Belbaraka

et al. 2009

Cases J

View full text Add to dashboard Cite

IntroductionPrimary lymphoma of the prostate is very rare. In this paper we present a case of early stage non-Hodgkin lymphoma of the prostate managed with six cycles of rituximab-based chemotherapy, and review the related literature.Case presentationAn 84-year-old man was admitted to our hospital having signs and symptoms suggestive of prostatic disease for 3 years. Histological and immunocytochemical studies of trans-urethral biopsy of the prostate showed diffuse large B-cell lymphoma. Radiological assessment of disease confirmed the diagnosis of early stage lymphoma of the prostate. The patient was managed by 6 of rituximab 375 mg/m2 on day 1, cyclophosphamide 750 mg/m2 on day 1, doxorubicin 50 mg/m2 on day 1, vincristine 1.4 mg/m2 on day 1, and prednisone 50 mg/m2 on days 1 to 5 with complete clinical and radiological response. He remained disease free, until now, 30 months after the end of chemotherapy.ConclusionAccording to the literature, the treatment and prognosis of primary lymphoma of the prostate is the same as that of other nodal lymphomas. Rituximab-based regimen should be considered in the management of prostatic diffuse large B-cell lymphoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Primary lymphoma of the prostate treated with rituximab-based chemotherapy: a case report and review of the literature

Taleb

Ismaili

Belbaraka

et al. 2009

Cases J

View full text Add to dashboard Cite

show abstract

“…Similarly, prostatic involvement is rarely encountered, with primary prostatic lymphomas representing approximately 0.2-0.8% of extranodal lymphomas, with urinary tract obstruction being the commonest presentation. [7] Secondary pancreatic involvement has been reported in only 0.2-2% of patients with NHL, out of which only two cases had B cell lymphoma, ours being the third case. [8] All the reports in literature give one rare site of extranodal involvement or a rare site of primary origin of lymphoma.…”

Section: Discussionmentioning

confidence: 90%

Four rare extranodal sites seen on FDG PET/CT in a single patient of disseminated lymphoma

Puranik

Agrawal

Purandare

et al. 2013

Indian Journal of Medical and Paediatric Oncology

View full text Add to dashboard Cite

show abstract

“…The diagnosis of most patients depends on autopsy [3] . Patel et al [5] reported a frequency of ＜10% of urinary tract involvement with non-Hodgkin's lymphoma, with ＜1% involving the prostate. Since the 1985 study of Bostwick and Mann [1] , at least 19 additional cases of non-Hodgkin's lymphoma have been reported.…”

Section: Discussionmentioning

confidence: 98%

Clinical analysis of 29 cases with primary malignant lymphoma of the prostate

Tong

2007

Chin. J. Clin. Oncol.

View full text Add to dashboard Cite

OBJECTIVE To summarize the clinical characteristics, pathology，treat-ment and prognosis of malignant lymphoma of the prostate. METHODS Clinical data from 29 patients with primary malignant lymphoma of the prostate were reviewed retrospectively. The median age was 66 years. Clinical signs and symptoms were due to lower urinary tract obstruction resulting from a diffusely enlarged prostate. Prostate biopsies revealed diffuse large B-cell non-Hodgkin's lymphoma. The therapeutic modalities included prostatectomy, radiotherapy and chemotherapy. RESULTS Extraprostatic involvement at various sites became evident in 19 of the 29 patients after diagnosis. Ten patients died from lymphoma with a median survival of 23 months (range, 2-30 months) . Seven patients were alive up to 60 months. CONCLUSION Malignant lymphoma involving the prostate was rare and has a rather poor prognosis. Prognosis related to the patient age，histo-logic type, and treatment or clinical stage of the disease at presentation.

show abstract

Primary prostatic involvement in non-hodgkin lymphoma

Cited by 30 publications

References 28 publications

Primary lymphoma of the prostate treated with rituximab-based chemotherapy: a case report and review of the literature

Primary lymphoma of the prostate treated with rituximab-based chemotherapy: a case report and review of the literature

Four rare extranodal sites seen on FDG PET/CT in a single patient of disseminated lymphoma

Clinical analysis of 29 cases with primary malignant lymphoma of the prostate

Contact Info

Product

Resources

About